- Profitability: Net income attributable to Golar of $141.1 million for the quarter, including:
- A $57.0 million realized gain (100% basis) on the FLNG Hilli Brent oil and TTF natural gas linked derivative instruments.
- A $12.4 million unrealized gain (100% basis) on the FLNG Hilli Brent oil and TTF natural gas linked derivative instruments.
- A $51.4 million unrealized mark-to-market gain recognized on Golar’s then 12.4 million NFE shares based on a September 30, 2022 carrying value of $43.71 per share.
- A $25.5 million unrealized gain on interest rate swaps.
- A $14.4 million reversal of Q1 and Q2 overproduction fees accrued in respect of FLNG Hilli.
- $10.0 million of net income from affiliates.
PTC Therapeutics Announces Results From MIT-E Clinical Trial Of Vatiquinone For The Treatment Of Mitochondrial Disease Associated Seizures
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated seizures (MDAS) failed to achieve its primary endpoint of reduction in